CTXR news

3 The company announced a 120% increase in LYMPHIR unit sales for Q4 2026 fueled by expanded commercial reach. The preliminary data indicates strong institutional demand and successful coverage expansion for the CTCL treatment.

Citus reported a 78% quarter-over-quarter increase in new institutions ordering LYMPHIR and raised revenue recognition via wholesale orders, signaling a strong commercial launch despite delayed revenue impact.

Context Therapeutics released a corporate presentation outlining its strategy for advancing T cell engager therapies targeting solid tumors. The presentation includes forward-looking statements regarding clinical development timelines, potential market opportunities, and funding requirements for the…

Citius Oncology presented Phase 1 data at ASCO showing LYMPHIR combined with pembrolizumab achieved 24% overall response rate and 48% clinical benefit rate in heavily pre-treated gynecologic cancer patients, including 33% response rate in endometrial cancer. The encouraging efficacy and tolerability…

Citius Oncology highlighted Phase 1 data for LYMPHIR combined with pembrolizumab showing 24% overall response rate and 20.5 months median progression-free survival in heavily pre-treated patients with recurrent or refractory gynecologic malignancies. The positive clinical signals in checkpoint inhib…